LivaNova PLC (NASDAQ:LIVN) Shares Acquired by Atria Investments Inc

Atria Investments Inc increased its holdings in LivaNova PLC (NASDAQ:LIVN) by 6.2% during the third quarter, HoldingsChannel.com reports. The fund owned 5,653 shares of the company’s stock after buying an additional 331 shares during the period. Atria Investments Inc’s holdings in LivaNova were worth $297,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently bought and sold shares of LIVN. Driehaus Capital Management LLC increased its position in LivaNova by 64.7% in the 2nd quarter. Driehaus Capital Management LLC now owns 544,042 shares of the company’s stock valued at $29,824,000 after acquiring an additional 213,749 shares during the period. Perceptive Advisors LLC grew its stake in shares of LivaNova by 48.5% in the 2nd quarter. Perceptive Advisors LLC now owns 444,000 shares of the company’s stock valued at $24,340,000 after purchasing an additional 145,000 shares during the last quarter. Great Lakes Advisors LLC acquired a new position in shares of LivaNova in the second quarter valued at approximately $16,614,000. Price T Rowe Associates Inc. MD raised its stake in shares of LivaNova by 6.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 31,021 shares of the company’s stock worth $1,736,000 after purchasing an additional 1,980 shares during the last quarter. Finally, Cornercap Investment Counsel Inc. acquired a new stake in shares of LivaNova during the second quarter worth $1,103,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

LivaNova Stock Down 0.7 %

Shares of NASDAQ:LIVN opened at $51.32 on Friday. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. The company has a market capitalization of $2.79 billion, a P/E ratio of 122.19 and a beta of 1.01. LivaNova PLC has a 52-week low of $42.75 and a 52-week high of $64.47. The stock’s fifty day simple moving average is $52.13 and its 200-day simple moving average is $52.60.

Analysts Set New Price Targets

LIVN has been the topic of several recent research reports. Robert W. Baird boosted their price objective on shares of LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. StockNews.com cut shares of LivaNova from a “strong-buy” rating to a “buy” rating in a report on Saturday, November 16th. Mizuho lowered their price objective on LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a report on Thursday, October 31st. The Goldman Sachs Group initiated coverage on LivaNova in a research note on Friday, October 4th. They set a “buy” rating and a $65.00 target price for the company. Finally, Baird R W upgraded LivaNova from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 17th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $69.17.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.